Metals accelerate production of the aberrant splicing isoform of the presenilin-2

Journal of Neurochemistry

Volumn 88, Issue 6, 2004, Pages 1345-1351

  Matsuzaki, Shinsuke ^a,b   Manabe, Takayuki ^a,b   Katayama, Taiichi ^a,b   Nishikawa, Atsuko ^a,b   Yanagita, Takeshi ^a,b   Okuda, Hiroaki ^a,b   Yasuda, Yuichi ^a,b,c   Miyata, Shingo ^a,b   Meshitsuka, Shunsuke ^d   Tohyama, Masaya ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c SYSMEX CORPORATION   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; HMGA1a; Hypoxia; Metal; Presenilin 2; Splicing

Indexed keywords

ALUMINUM; HIGH MOBILITY GROUP A1A PROTEIN; MESSENGER RNA PRECURSOR; METAL DERIVATIVE; PRESENILIN 2;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENDOPLASMIC RETICULUM; EXON; GENE INDUCTION; HUMAN; HUMAN CELL; HYPOXIA; LONG TERM EXPOSURE; NEUROBLASTOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; RNA SPLICING;

EID: 12144288051     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02290.x     Document Type: Article

References (36)

1. Alfrey A. C., LeGendre G. R. and Kaehny W. D. (1976) The dialysis encephalopathy syndrome: possible aluminum intoxication. N. Engl. J. Med. 294, 184-188.
2. American Academy of Pediatrics Committee on Nutrition (1986) Aluminum toxicity in infants and children. Pediatrics 78, 1150-1154.
3. ATSDR (1999) Toxicological Profile for Aluminum (Update): Agency for Toxic Substances and Disease Registry (ATSDR). U.S. Department of Health and Human Services, USA.
4. Borgern D. R. and Essig D. A. (1998) Induction of HSP 32 gene in hypoxic cardiomyocytes is attenuated by treatment with N-acetyl-L-cystein. Am. J. Physiol. 274, H965-H973.
5. Bush A. I. (2003) The metallobiology of Alzheimer's disease. Trends Neurosci. 26, 207-214.
6. Crapper D. R., Quittkat S., Krishnan S. S., Dalton A. J. and DeBoni U. (1980) Intranuclear aluminum content in Alzheimer's disease, dialysis encephalopathy, and experimental aluminum encephalopathy. Acta Neuropathol. (Berl.) 50, 19-24.
7. Curtain C. C., Ali F., Volitakis I., Cherny R. A., Norton R. S., Beyreuther K., Barrow C. J., Masters C. L., Bush A. I. and Barnham K. J. (2001) Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276, 20466-20473.
8. Finnegan M. M., Retting S. J. and Orvig C. (1986) A neutral water-soluble aluminum complex of neurological interest. J. Am. Chem. Soc. 108, 5033-5035.
9. Gawlick D., Bratter P., Gatschke W. and Meyer-Sabellek W. (1987) Aluminum in the Maintenance Diet of Rats, In: Trace Element Analytical Chemistry in Medicine and Biology (P. Bratter and P. Schramel, eds), Vol. 4, pp. 431-442. Walter de Gruyter Co., New York.
10. Goate A., Chartier-Harlin M. C., Mullan M. et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706.
11. Katayama T., Imaizumi K., Sato N. et al. (1999) Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat. Cell. Biol. 1, 475-485.
12. Kennard M. L., Feldman H., Yamada T. and Jefferies W. A. (1996) Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat. Med. 2, 1230-1235.
13. Linder M. C. and Hazegh-Azam M. (1996) Copper biochemistry and molecular biology. Am. J. Clin. Nutr. 63, 797S-811S.
14. Loeffler D. A., Connor J. R., Juneau P. L., Snyder B. S., Kanaley L., DeMaggio A. J., Nguyen H., Brickman C. M. and LeWitt P. A. (1995) Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 65, 710-716.
15. Manabe T., Kitayama T., Ogita K. and Yoneda Y. (2000) Differential expression and phosphorylation of particular Fos family members by kainate in nuclear and cytosolic fractions of murine hippocampus. Neuroscience 100, 453-463.
16. Manabe T., Kuramoto N., Nakamichi N., Aramachi K., Baba K., Hirai T., Yoneyama M. and Yoneda Y. (2001a) Degradation of c-Fos protein expressed by N-methyl-D-aspartic acid in nuclear fractions of murine hippocampus. Brain Res. 905, 34-43.
17. Manabe T., Ogita K., Nakamichi N. and Yoneda Y. (2001b) Differential in vitro degradation of particular Fos family members expressed by kainic acid in nuclear and cytosolic fractions of murine hippocampus. J. Neurosci. Res. 64, 34-42.
18. Manabe T., Katayama T., Sato N., Kudo T., Matsuzaki M., Imaizumi K. and Tohyama M. (2002) The cytosolic inclusion bodies that consists of splice variants that lack exon 5 of the presenilin-2 gene differ obviously from Hirano bodies observed in the brain from sporadic cases of Alzheimer's disease patients. Neurosci. Let. 328, 198-200.
19. Manabe T., Katayama T., Sato N. et al. (2003) Induced HMGA1a expression causes aberrant splicing of presenilin-2 pre-mRNA in sporadic Alzheimer's disease. Cell Death Differ. 10, 698-708.
20. Markesbery W. R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134-147.
21. Martyn C. N., Barker D. J., Osmond C., Harris E. C., Edwardson J. A. and Lacey R. F. (1989) Geographical relation between Alzheimer's disease and aluminum in drinking water. Lancet 14, 1 (8629), 59-62.
22. Meshitsuka S. and Inoue M. (1998) Urinary excretion of aluminum from antacid ingestion and estimation of its apparent biological halftime. Trace Elements Electroly. 15, 132-135.
23. Meshitsuka S., Matsushima F. and Nose T. (1999) Absorption of aluminum from aspirin preparations with aluminum glycinate. Trace Elements Electroly. 16, 175-176.
24. Multhaup G. (1997) Amyloid precursor protein, copper and Alzheimer's disease. Biomed. Pharmacother. 51, 105-111.
25. Multhaup G., Schlicksupp A., Hesse L. et al. (1996) The amyloid precursor protein of Alzheimer's disease in the reduction of copper (II) to copper (I). Science 271, 1406-1409.
26. Multhaup G., Masters C. L. and Beyreuther K. (1998) Oxidative stress in Alzheimer's disease. Alzheimer Rep. 1, 147-154.
27. Pratico D., Uryu K., Sung S., Tang S., Trojanowski J. Q. and Lee V. M. (2002) Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J. 16, 1138-1140.
28. Rogaev E. I., Sherrington R., Rogaeva E. A. et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778.
29. Sato N., Hori O., Yamaguchi A. et al. (1999) A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue. J. Neurochem. 72, 2498-2505.
30. Sato N., Imaizumi K., Manabe T. et al. (2001) Increased production of β-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin-2. J. Biol. Chem. 276, 2108-2114.
31. Savory J., Rao J. K., Huang Y., Letada P. R. and Herman M. M. (1999) Age-related hippocampal changes in Bcl-2. Bax ratio, oxidative stress, redox-active iron and apoptosis associated with aluminum-induced neurodegeneration: increased susceptibility with aging. Neurotoxicology. 20, 805-817.
32. Schreiber E., Matthias P., Muller M. M. and Schaffner W. (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17, 6419.
33. Selkoe D. J. (1994) Normal and abnormal biology of the beta-amyloid precursor protein. Annu. Rev. Neurosci. 17, 489-517.
34. Smith M. A., Richey Harris P. L., Sayre L. and Perry G. (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl Acad. Sci. USA 94, 9866-9868.
35. White A. R., Huang X., Jobling M. F., Barrow C. J., Beyreuther K., Masters C. L., Bush A. I. and Cappai R. (2001) Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J. Neurochem. 76, 1509-1520.
36. Yoneda Y., Ogita K., Azuma Y., Ikeda M., Tagami H. and Manabe T. (1999) N-Methyl-D-aspartate signaling to nuclear activator protein-1 through mechanisms different from those for kainate signaling in murine brain. Neuroscience 90, 519-533.